Clinical trials: Extensive Disease Small Cell Lung Cancer
Small Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory.
- Trial name
- NCT06780137
- Testing
- Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab
- Where
- 48 sites in United States, Argentina and 10 more
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer, Small Cell Lung Cancer
Prospective Observational Study on ES-SCLC
Study Title: A Real-World Study on Extensive-Stage Small Cell Lung Cancer (ES-SCLC) What is this study about? This research aims to learn more about how patients with extensive-stage small cell lung cancer (ES-SCLC) are treated…
- Trial name
- NCT07173946
- Testing
- Standard of Care Anti-tumor Therapy
- Volunteers
- 96 people
- Sponsor
- Peking Union Medical College Hospital
SCLC
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer
- Trial name
- NCT05844150
- Testing
- PM8002, Platinum, Etoposide
- Where
- 17 sites in China
- Volunteers
- 50 people
- Sponsor
- Biotheus Inc.
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
- Trial name
- DeLLphi-305 (NCT06211036)
- Testing
- Tarlatamab, Durvalumab
- Where
- 219 sites in United States, Argentina and 27 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Lung Cancer
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087048
- Testing
- topotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer
The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions.
- Trial name
- NCT06530797
- Testing
- First-line Adebrelimab regiment for advanced stage ES-SCLC, Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Small Cell Lung Cancer
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC).
- Trial name
- NCT02735980
- Testing
- Prexasertib
- Where
- 41 sites in United States, France and 8 more
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Carcinoma
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
To show that maintenance therapy with Tislelizumab plus Anlotinib will prolong Progression Free Survival in subjects with extensive stage disease small cell lung cancer who have completed first line chemotherapy.
- Trial name
- NCT04620837
- Testing
- Tislelizumab, Anlotinib hydrochloride
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese Academy of Medical Sciences
SCLC,Extensive Stage
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
This is an open-label, single arm, phase 2 trial enrolling patients with untreated Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.
- Trial name
- THOR (NCT05623319)
- Testing
- Pembrolizumab/Olaparib
- Where
- 12 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
This research study is being done to assess the safety and tolerability of study drugs, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) and nivolumab in subjects with small cell lung cancer or advanced or inoperable neuroendocrine tumor…
- Trial name
- NCT03325816
- Testing
- Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Immunotherapy, Second-line Treatment
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer
- Trial name
- NCT05901584
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
Small Cell Lung Carcinoma
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer…
- Trial name
- NCT03963414
- Testing
- Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Nebraska
Breast Cancer, Colorectal Cancer
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to the cancer cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00128622
- Testing
- denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- H. Kim Lyerly
Lung Cancer, Metastatic Cancer
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment for primary lung cancer or lung metastases that cannot be removed by surgery.
- Trial name
- NCT00303901
- Testing
- cryosurgery, positron emission tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Extensive Stage Small Cell Lung Cancer, Lung Metastases
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II study is studying how well giving AZD0530 works in treating patients with extensive-stage small cell lung cancer.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Lung Metastases, Malignant Pleural Effusion, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00528645
- Testing
- saracatinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Small Cell
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the…
- Trial name
- NCT06698965
- Testing
- Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Small Cell Lung Cancer
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
This proposed Phase II trial will investigate the combination of irinotecan and carboplatin followed by sunitinib in the first-line treatment of patients with extensive-stage SCLC.
- Trial name
- NCT00695292
- Testing
- irinotecan, Carboplatin, sunitinib
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer, Small Cell Lung Cancer
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
The purpose of this study was to evaluate the efficacy and safety of combining durvalumab with EP followed by durvalumab + olaparib maintenance therapy as first-line treatment in patients with extensive-disease small-cell lung…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Durvalumab
- Trial name
- NCT05245994
- Testing
- Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Li Zhang, MD
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)